In summary, modern imaging techniques, encompassing tau-, amyloid- and TSPO-PET to assess Alzheimer’s disease copathology and neuroinflammation, along with FDG-PET have demonstrated efficacy in the identification of early neurodegenerative alterations associated with cognitive decline in Parkinson’s disease. This evidence concerns the gene MAPT and Parkinson disease.